etravirine ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antivirals Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI) 1115 269055-15-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • etravirine
  • intelence
  • etravirin
  • R-165335
  • TMC-125
HIV-1 reverse transriptase inhibitor; an anti-HIV agent
  • Molecular weight: 435.29
  • Formula: C20H15BrN6O
  • CLOGP: 5.17
  • LIPINSKI: 1
  • HAC: 7
  • HDO: 2
  • TPSA: 120.64
  • ALOGS: -4.41
  • ROTB: 4

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.40 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 6.56 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Approvals:

DateAgencyCompanyOrphan
Aug. 28, 2008 EMA
Jan. 18, 2008 FDA JANSSEN R AND D

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Enlarged clitoris 208.51 43.20 28 2401 130 63486463
Hyperandrogenism 191.70 43.20 25 2404 88 63486505
Viral mutation identified 170.79 43.20 33 2396 1777 63484816
Foetal exposure during pregnancy 167.73 43.20 58 2371 31904 63454689
Exposure during pregnancy 167.41 43.20 92 2337 155455 63331138
Virologic failure 145.51 43.20 29 2400 1833 63484760
Lipodystrophy acquired 127.92 43.20 25 2404 1427 63485166
Cloacal exstrophy 109.37 43.20 16 2413 150 63486443
Congenital genital malformation 102.49 43.20 15 2414 141 63486452
Bladder agenesis 102.21 43.20 15 2414 144 63486449
Genitalia external ambiguous 101.56 43.20 15 2414 151 63486442
Caudal regression syndrome 100.60 43.20 15 2414 162 63486431
Meconium stain 98.69 43.20 15 2414 186 63486407
Abortion spontaneous 98.68 43.20 44 2385 47151 63439442
Gastrointestinal disorder congenital 95.81 43.20 14 2415 130 63486463
Anal atresia 95.38 43.20 16 2413 382 63486211
Tethered cord syndrome 93.51 43.20 15 2414 269 63486324
Meningomyelocele 88.35 43.20 16 2413 602 63485991
Gastrointestinal malformation 84.54 43.20 13 2416 175 63486418
Exomphalos 83.42 43.20 15 2414 542 63486051
Umbilical cord abnormality 80.81 43.20 15 2414 648 63485945
Premature baby 79.95 43.20 30 2399 20705 63465888
Immune reconstitution inflammatory syndrome 69.38 43.20 20 2409 6064 63480529
Premature labour 66.66 43.20 23 2406 12481 63474112
Pathogen resistance 64.00 43.20 19 2410 6379 63480214
Drug resistance 63.12 43.20 26 2403 22907 63463686
Neural tube defect 61.68 43.20 10 2419 192 63486401
Congenital ectopic bladder 60.28 43.20 9 2420 98 63486495
Anencephaly 57.50 43.20 10 2419 297 63486296
Congenital anomaly 55.40 43.20 13 2416 1763 63484830
Spina bifida 53.00 43.20 11 2418 848 63485745
Sepsis neonatal 46.86 43.20 9 2420 467 63486126
Treatment noncompliance 45.26 43.20 24 2405 37301 63449292
Amniotic cavity infection 43.39 43.20 10 2419 1253 63485340

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Lipodystrophy acquired 470.08 24.40 106 4802 3238 34948785
Mitochondrial toxicity 414.52 24.40 92 4816 2607 34949416
Progressive external ophthalmoplegia 387.61 24.40 78 4830 1357 34950666
Eyelid ptosis 349.86 24.40 93 4815 5673 34946350
Diplopia 233.38 24.40 88 4820 16755 34935268
Virologic failure 219.87 24.40 58 4850 3422 34948601
Drug interaction 155.97 24.40 174 4734 225772 34726251
Viral mutation identified 120.78 24.40 35 4873 2919 34949104
Ophthalmoplegia 103.54 24.40 28 4880 1812 34950211
Drug resistance 100.99 24.40 56 4852 25871 34926152
Pathogen resistance 71.17 24.40 32 4876 9450 34942573
CD4 lymphocytes decreased 59.66 24.40 18 4890 1723 34950300
Cytomegalovirus chorioretinitis 54.17 24.40 20 4888 3569 34948454
Fibrous histiocytoma 49.73 24.40 10 4898 172 34951851
Viral load increased 49.16 24.40 17 4891 2510 34949513
Adrenal suppression 46.71 24.40 12 4896 635 34951388
Drug level increased 43.54 24.40 31 4877 22065 34929958
Immune reconstitution inflammatory syndrome 42.73 24.40 22 4886 8737 34943286
Multiple-drug resistance 37.15 24.40 17 4891 5222 34946801
Heart transplant rejection 34.87 24.40 11 4897 1220 34950803
Renal tubular disorder 32.71 24.40 15 4893 4628 34947395
Hepatic steatosis 32.17 24.40 24 4884 18338 34933685
Hepatic cirrhosis 31.16 24.40 23 4885 17291 34934732
Drug level decreased 30.65 24.40 17 4891 7829 34944194
Blood creatine phosphokinase abnormal 30.28 24.40 7 4901 237 34951786
Osteoporosis 30.21 24.40 20 4888 12648 34939375
Hepatitis C 29.64 24.40 18 4890 9812 34942211
Hepatitis 28.61 24.40 25 4883 23879 34928144
Opportunistic infection 27.85 24.40 10 4898 1648 34950375
Choroiditis 26.87 24.40 9 4899 1206 34950817
Viraemia 26.71 24.40 9 4899 1229 34950794

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Lipodystrophy acquired 554.03 26.20 112 5357 4213 79734706
Mitochondrial toxicity 460.95 26.20 91 5378 3023 79735896
Progressive external ophthalmoplegia 449.48 26.20 79 5390 1366 79737553
Eyelid ptosis 341.48 26.20 90 5379 10954 79727965
Virologic failure 282.62 26.20 64 5405 4127 79734792
Viral mutation identified 255.19 26.20 58 5411 3800 79735119
Diplopia 235.87 26.20 88 5381 33378 79705541
Drug interaction 176.93 26.20 177 5292 415006 79323913
Drug resistance 125.08 26.20 60 5409 42153 79696766
Ophthalmoplegia 105.75 26.20 27 5442 2885 79736034
Pathogen resistance 105.64 26.20 39 5430 14303 79724616
Immune reconstitution inflammatory syndrome 88.72 26.20 34 5435 13807 79725112
Multiple-drug resistance 65.03 26.20 24 5445 8784 79730135
Abortion spontaneous 61.24 26.20 33 5436 29474 79709445
Exposure during pregnancy 59.88 26.20 52 5417 101080 79637839
Adrenal suppression 50.93 26.20 13 5456 1386 79737533
Hepatic cirrhosis 43.31 26.20 28 5441 34878 79704041
Fibrous histiocytoma 43.18 26.20 10 5459 709 79738210
Blood HIV RNA increased 43.01 26.20 12 5457 1796 79737123
Renal tubular disorder 41.79 26.20 16 5453 6470 79732449
Treatment noncompliance 41.71 26.20 32 5437 52236 79686683
Hepatitis C 41.61 26.20 19 5450 11906 79727013
Genotype drug resistance test positive 37.24 26.20 10 5459 1298 79737621
Drug level decreased 32.39 26.20 17 5452 14385 79724534
Choroiditis 32.09 26.20 9 5460 1372 79737547
Mycobacterium avium complex infection 31.99 26.20 12 5457 4588 79734331
Hepatic steatosis 29.87 26.20 23 5446 37715 79701204
Hepatitis 29.66 26.20 27 5442 55700 79683219
Premature labour 28.12 26.20 13 5456 8377 79730542
Oesophageal candidiasis 26.95 26.20 13 5456 9205 79729714
Amniotic cavity infection 26.77 26.20 7 5462 820 79738099
Anogenital dysplasia 26.40 26.20 5 5464 132 79738787
CD4 lymphocytes decreased 26.36 26.20 9 5460 2625 79736294
Lipohypertrophy 26.31 26.20 7 5462 877 79738042

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J05AG04 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Non-nucleoside reverse transcriptase inhibitors
FDA MoA N0000009948 Non-Nucleoside Reverse Transcriptase Inhibitors
FDA EXT N0000175460 Non-Nucleoside Analog
FDA EPC N0000175463 Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000998 Antiviral Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D019384 Nucleic Acid Synthesis Inhibitors
MeSH PA D018894 Reverse Transcriptase Inhibitors
FDA MoA N0000182140 Cytochrome P450 2C19 Inhibitors
FDA MoA N0000185503 P-Glycoprotein Inhibitors
FDA MoA N0000185504 Cytochrome P450 2C9 Inhibitors
FDA MoA N0000190118 Cytochrome P450 3A Inducers
CHEBI has role CHEBI:22587 antiviral agents
CHEBI has role CHEBI:53756 reverse transcriptase inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Human immunodeficiency virus infection indication 86406008 DOID:526
Chronic type B viral hepatitis contraindication 61977001
Chronic hepatitis C contraindication 128302006
Liver function tests abnormal contraindication 166603001
Peripheral nerve disease contraindication 302226006
Breastfeeding (mother) contraindication 413712001




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 3.78 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Canalicular multispecific organic anion transporter 1 Transporter IC50 5.11 CHEMBL
Multidrug resistance-associated protein 1 Transporter IC50 5.07 CHEMBL
ATP-binding cassette sub-family G member 2 Transporter IC50 5.22 CHEMBL
Canalicular multispecific organic anion transporter 2 Transporter IC50 5.29 CHEMBL
Multidrug resistance protein 1 Transporter IC50 5.12 CHEMBL
Reverse transcriptase/RNaseH Enzyme INHIBITOR IC50 9.22 CHEMBL CHEMBL
Gag-Pol polyprotein Polyprotein IC50 9 WOMBAT-PK
Cruzipain Enzyme IC50 5.40 CHEMBL
Reverse transcriptase Enzyme IC50 8 CHEMBL
Reverse transcriptase protein Unclassified IC50 8.89 CHEMBL

External reference:

IDSource
4027244 VUID
N0000179781 NUI
D04112 KEGG_DRUG
4027244 VANDF
C1456409 UMLSCUI
CHEBI:63589 CHEBI
65B PDB_CHEM_ID
CHEMBL308954 ChEMBL_ID
DB06414 DRUGBANK_ID
C451734 MESH_SUPPLEMENTAL_RECORD_UI
12675 IUPHAR_LIGAND_ID
8303 INN_ID
0C50HW4FO1 UNII
193962 PUBCHEM_CID
475969 RXNORM
130981 MMSL
24971 MMSL
348481 MMSL
d07076 MMSL
012527 NDDF
432121008 SNOMEDCT_US
432221004 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
etravirine HUMAN PRESCRIPTION DRUG LABEL 1 42291-473 TABLET 100 mg ORAL ANDA 25 sections
etravirine HUMAN PRESCRIPTION DRUG LABEL 1 42291-474 TABLET 200 mg ORAL ANDA 25 sections
Intelence HUMAN PRESCRIPTION DRUG LABEL 1 53808-0787 TABLET 100 mg ORAL NDA 31 sections
Intelence HUMAN PRESCRIPTION DRUG LABEL 1 54868-5864 TABLET 100 mg ORAL NDA 30 sections
Intelence HUMAN PRESCRIPTION DRUG LABEL 1 54868-6368 TABLET 200 mg ORAL NDA 30 sections
Intelence HUMAN PRESCRIPTION DRUG LABEL 1 59676-570 TABLET 100 mg ORAL NDA 31 sections
Intelence HUMAN PRESCRIPTION DRUG LABEL 1 59676-570 TABLET 100 mg ORAL NDA 31 sections
Intelence HUMAN PRESCRIPTION DRUG LABEL 1 59676-570 TABLET 100 mg ORAL NDA 31 sections
Intelence HUMAN PRESCRIPTION DRUG LABEL 1 59676-571 TABLET 200 mg ORAL NDA 31 sections
Intelence HUMAN PRESCRIPTION DRUG LABEL 1 59676-571 TABLET 200 mg ORAL NDA 31 sections
Intelence HUMAN PRESCRIPTION DRUG LABEL 1 59676-571 TABLET 200 mg ORAL NDA 31 sections
Intelence HUMAN PRESCRIPTION DRUG LABEL 1 59676-572 TABLET 25 mg ORAL NDA 31 sections
Intelence HUMAN PRESCRIPTION DRUG LABEL 1 59676-572 TABLET 25 mg ORAL NDA 31 sections
Intelence HUMAN PRESCRIPTION DRUG LABEL 1 59676-572 TABLET 25 mg ORAL NDA 31 sections
etravirine HUMAN PRESCRIPTION DRUG LABEL 1 60219-1720 TABLET 25 mg ORAL ANDA 26 sections
etravirine HUMAN PRESCRIPTION DRUG LABEL 1 60219-1720 TABLET 25 mg ORAL ANDA 26 sections
etravirine HUMAN PRESCRIPTION DRUG LABEL 1 60219-1721 TABLET 100 mg ORAL ANDA 26 sections
etravirine HUMAN PRESCRIPTION DRUG LABEL 1 60219-1721 TABLET 100 mg ORAL ANDA 26 sections
etravirine HUMAN PRESCRIPTION DRUG LABEL 1 60219-1722 TABLET 200 mg ORAL ANDA 26 sections
etravirine HUMAN PRESCRIPTION DRUG LABEL 1 60219-1722 TABLET 200 mg ORAL ANDA 26 sections
etravirine HUMAN PRESCRIPTION DRUG LABEL 1 69238-1720 TABLET 25 mg ORAL ANDA 26 sections
etravirine HUMAN PRESCRIPTION DRUG LABEL 1 69238-1721 TABLET 100 mg ORAL ANDA 26 sections
etravirine HUMAN PRESCRIPTION DRUG LABEL 1 69238-1722 TABLET 200 mg ORAL ANDA 26 sections
ETRAVIRINE HUMAN PRESCRIPTION DRUG LABEL 1 69315-285 TABLET 100 mg ORAL ANDA 22 sections
ETRAVIRINE HUMAN PRESCRIPTION DRUG LABEL 1 69315-286 TABLET 200 mg ORAL ANDA 22 sections
ETRAVIRINE HUMAN PRESCRIPTION DRUG LABEL 1 80005-112 TABLET 100 mg ORAL ANDA 22 sections
ETRAVIRINE HUMAN PRESCRIPTION DRUG LABEL 1 80005-113 TABLET 200 mg ORAL ANDA 22 sections